CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Sublocadedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04060654
NCT04060654Phase 4Completed
CompareCT.gov

An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE™)

Indivior Inc.·interventional·Posted Aug 19, 2019·Updated Mar 25, 2025

In Brief

A Phase 4 clinical trial evaluating Sublocade for Opioid Use Disorder, Severe and Opioid Use Disorder, Moderate. Completed, enrolled 17 participants across 1 site.

Detailed Summary

A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder, Severe, Opioid Use Disorder, Moderate
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedAug 19, 2019
Enrollment StartOct 21, 2019
Primary CompletionMay 15, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.9 years ago

Interventions

Sublocadedrug

SUBLOCADE to be administered approximately every 4 weeks per local standard of care